RT Journal Article
SR Electronic
T1 Assessment of serological assays for identifying high titer convalescent plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.26.21254427
DO 10.1101/2021.03.26.21254427
A1 Farnsworth, Christopher W.
A1 Case, James Brett
A1 Hock, Karl
A1 Chen, Rita E.
A1 O’Halloran, Jane A.
A1 Presti, Rachel
A1 Goss, Charles W.
A1 Rauseo, Adriana M.
A1 Ellebedy, Ali
A1 Theel, Elitza S.
A1 Diamond, Michael S.
A1 Henderson, Jeffrey P.
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2021.03.26.21254427.abstract
AB The COVID-19 pandemic has been accompanied by the largest mobilization of therapeutic convalescent plasma (CCP) in over a century. Initial identification of high titer units was based on dose-response data using the Ortho VITROS IgG assay. The proliferation of SARS-CoV-2 serological assays and non-uniform application has led to uncertainty about their interrelationships. The purpose of this study was to establish correlations and analogous cutoffs between commercially available serological tests (Ortho, Abbott, Roche), a spike ELISA, and a virus neutralization assay using convalescent plasma from a cohort of 79 donors from April 2020. Relationships relative to FDA-approved cutoffs under the CCP EUA were identified by linear regression and receiver operator characteristic curves. Relative to the Ortho VITROS assay, the r2 of the Abbott, Roche, the anti-Spike ELISA and the neutralizing assay were 0.58, 0.5, 0.82, and 0.44, respectively. The best correlative index for establishing high-titer units was 3.82 S/C for the Abbott, 10.89 COI for the Roche, 1:1,202 for the anti-Spike ELISA, and 1:200 by the neutralization assay. The overall agreement using derived cutoffs compared to the CCP EUA Ortho VITROS cutoff of 9.5 was 92.4% for Abbott, 84.8% for Roche, 87.3% for the anti-S ELISA and 78.5% for the neutralization assay. Assays based on antibodies against the nucleoprotein (Roche, Abbott) and neutralizing antibody tests were positively associated with the Ortho assay, although their ability to distinguish FDA high-titer specimens was imperfect. The resulting relationships help reconcile results from the large body of serological data generated during the COVID-19 pandemic.Competing Interest StatementCWF: Research funding: Abbott Diagnostics, Beckman Coulter, Siemens Healthineers. Consulting: Roche Diagnostics. JPH: Consulting: Immunome, Inc. EST: Consulting/Advisory Board: Roche Diagnostics, Accelerate Diagnostics, Serimmune Inc.Funding StatementThis study utilized samples obtained from the Washington University School of Medicine COVID-19 biorepository, which is supported by: the Barnes-Jewish Hospital Foundation; the Siteman Cancer Center grant P30 CA091842 from the National Cancer Institute of the National Institutes of Health; and the Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 from the National Center for Advancing Translational Sciences of the National Institutes of Health. J.P.H. acknowledges support from National Institute of Diabetes and Digestive and Kidney Diseases grant RO1DK111930 and the Longer Life Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Washington University Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request at the discretion of the authors